Fig. 1



Human Plasma
0 1 2 4 24 48 96 0 1 2 4 24 48 96 Hours
SEQ ID NO:2
SEQ ID NO:25
Mouse Plasma
0 1 2 4 24 48 96 0 1 2 4 24 48 96 Hours
SEQ ID NO:2
SEQ ID NO:25

Fig. 2A



Mock
1 10 25 1 10 25
12 hours 24 hours
1 10 25
Mock
1 10 25
48 hours
Bcl-2
Survivin

Fig. 2B



24h Survivin ELISA
% of mock
180
160
140
120
100
80
60
40
20
0
0.04nM SEQ ID 2
0.2nM SEQ ID 2
1nM SEQ ID 2
5nM SEQ ID 2
5nM SEQ ID 24
MOCK
MOCK

Fig. 2C



140
120
100
80
60
40
20
0
5nM
SEQ ID 2
5nM
SEQ ID 24
MOCK
MOCK
Full
2B
Ex3

Fig. 3



Fold induction / Relative to mock
0
1
2
3
4
5
6
7
8
13H_Average
24H_Average
48H_Average
72H_Average
Mock
0,2 nM
1 nM
5 nM
25 nM
100 nM
0,2 nM
1 nM
5 nM
25 nM
100 nM
SEQ ID NO:2
SEQ ID NO:24
Oligo/Conc (nM)

Fig. 4



80
70
60
50
40
30
20
10
0
Non-apoptotic cells
Early-apoptotic cells
Late-apoptotic cells
Damaged cells
Mock
Mock
5 nM SEQ ID NO:2
25 nM SEQ ID NO:2
5 nM SEQ ID NO:24
25 nM SEQ ID NO:24

Fig. 5



13H_Average
24H_Average
48H_Average
72H_Average
Fold reduction / Relative to mock
140
120
100
80
60
40
20
0
0,2 nM
1 nM
5 nM
25 nM
100 nM
0,2 nM
1 nM
5 nM
25 nM
100 nM
Mock
SEQ ID NO:2
SEQ ID NO:24
Oligo(conc (nM)

Fig. 6A



Fold Induction of apoptosis following AS survivin treatment
Fold Induction
20,00
18,00
16,00
14,00
12,00
10,00
8,00
6,00
4,00
2,00
0,00
24T
48T
72T
Mock
10nM Taxol
10 nM SEQ ID NO:22
100nM Taxol
10 nM SEQ ID NO:22
10nM Taxol
10 nM SEQ ID NO:2
100nM Taxol
10 nM SEQ ID NO:2
10nM Taxol
100nM Taxol
10 nM SEQ ID NO:22
10 nM SEQ ID NO:2
0,1 % DMSO
Oligo/treatment

Fig. 6B



150%
100%
50%
0%
Mock, 0,1% DMSO
SEQID 2, 2nM
Mock, 10nM Taxol
SEQID 2, 2nM + 10nM Taxol
Mock, 0,1% DMSO
SEQID 2, 2nM
Mock, 10nM Taxol
SEQID 2, 2nM + 10nM Taxol
Compounds
24 hours
48 hours

Fig. 6C



160%
140%
120%
100%
80%
60%
40%
20%
0%
Percent of Mock
MOCK
SEQ ID NO:26
SEQ ID NO:2
SEQ ID's NO:2+26
SEQ ID's NO:2+24
SEQ ID's NO:2+27
SEQ ID NO:27
SEQ ID NO:24
oligos
10 nM
Bcl-2/Gap
Survivin/Gap

Fig. 7A







Fig. 7B


24 hours
Mock 0.1% DMSO
G0G1
55%
S
23%
G2
13%
10nM Taxol
0.1% DMSO
G0G1
15
S
15%
G2
25%
SEQ ID 2, 2nM
0.1% DMSO
G0G1
25%
S
27%
G2
27%
SEQ ID 2, 2nM
Taxol, 10nM
0.1% DMSO
G0G1
12%
S
15%
G2
36%
SEQ ID 24, 10nM
0.1% DMSO
G0G1
40%
S
23%
G2
18%
SEQ ID 24, 10nM
Taxol, 10nM
0.1% DMSO
G0G1
13%
S
17%
G2
29%



	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
Oligo: A schedule																							
Oligo: B schedule																							
Taxol: A & B schedule																							

Fig. 9


Survivin protein levels in tumour
Vehicle
SEQ ID NO:2
Vehicle
SEQ ID NO:2
M31
32
36
37
33
34
38
39
40



% SurvivinmRNA levels in Tumour
140
120
100
80
60
40
20
Vehicle
SEQ ID NO:2

Fig. 10A




Fig. 10B





Fig. 1


Human Plasma
0 1 2 4 24 48 96 0 1 2 4 24 48 96 Hours
SEQ ID NO:2
SEQ ID NO:25



Mouse Plasma
0 1 2 4 24 48 96 0 1 2 4 24 48 96 Hours
SEQ ID NO:2
SEQ ID NO:25

Fig. 2A



Mock
1
10
25
1
10
25
Mock
1
10
25
12 hours
24 hours
48 hours
Bcl-2
Survivin

Fig. 2B



24h Survivin ELISA
% of mock
180
160
140
120
100
80
60
40
20
0
0.04nM SEQ ID 2
0.2nM SEQ ID 2
1nM SEQ ID 2
5nM SEQ ID 2
5nM SEQ ID 24
MOCK
MOCK

Fig. 2C



140
120
100
80
60
40
20
0
5nM
SEQ ID 2
5nM
SEQ ID 24
MOCK
MOCK
Full
2B
Ex3

Fig. 3



13H_Average
24H_Average
48H_Average
72H_Average
Fold Induction / Relative to mock
0
1
2
3
4
5
6
7
8
Mock
0,2 nM
1 nM
5 nM
25 nM
100 nM
SEQ ID NO:2
0,2 nM
1 nM
5 nM
25 nM
100 nM
SEQ ID NO:24
Oligo/Conc (nM)

Fig. 4



80
70
60
50
40
30
20
10
0
Non-apoptotic cells
Early-apoptotic cells
Late-apoptotic cells
Damaged cells
Mock
Mock
5 nM SEQ ID NO:2
25 nM SEQ ID NO:2
5 nM SEQ ID NO:24
25 nM SEQ ID NO:24

Fig. 5



13H_Average
24H_Average
48H_Average
72H_Average
Fold reduction / Relative to mock
140
120
100
80
60
40
20
0
0,2 nM
1 nM
5 nM
25 nM
100 nM
0,2 nM
1 nM
5 nM
25 nM
100 nM
Mock
SEQ ID NO:2
SEQ ID NO:24
Oligo(conc (nM)

Fig. 6A



Fold Induction of apoptosis following AS survivin treatment
Fold Induction
20,00
18,00
16,00
14,00
12,00
10,00
8,00
6,00
4,00
2,00
0,00
24T
48T
72T
Mock
10nM Taxol
10 nM SEQ ID NO:22
100nM Taxol
10 nM SEQ ID NO:22
10nM Taxol
10 nM SEQ ID NO:2
100nM Taxol
10 nM SEQ ID NO:2
10nM Taxol
100nM Taxol
10 nM SEQ ID NO:22
10 nM SEQ ID NO:2
0,1 % DMSO
Oligo/treatment

Fig. 6B



150%
100%
50%
0%
Mock, 0,1% DMSO
SEQID2, 2nM
Mock, 10nM Taxol
SEQID2, 2nM+ 10nM Taxol
Mock, 0,1% DMSO
SEQID2, 2nM
Mock, 10nM Taxol
SEQID2, 2nM+ 10nM Taxol
Compounds
24 hours
48 hours

Fig. 6C



160%
140%
120%
100%
80%
60%
40%
20%
0%
Percent of Mock
MOCK
SEQ ID NO:26
SEQ ID NO:2
SEQ ID's NO:2+26
SEQ ID's NO:26+24
SEQ ID's NO:2+27
SEQ ID NO:27
SEQ ID NO:24
oligos
10 nM
Bcl-2/Gap
Survivin/Gap

Fig. 7A






Mock
SEQ ID 2 (2nM)
G0/G1
G2
G0/G1
G2
24 hours
G0/G1
G2
G0/G1
G2
+Taxol
G0/G1
G2
G0/G1
G2
48hours
G0/G1
G2
G0/G1
G2
G4
+Taxol


Fig. 7B


24 hours


















	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
Oligo: A schedule																							
Oligo: B schedule																							
Taxol: A & B schedule																							

Fig. 9


Survivin protein levels in tumour
Vehicle
SEQ ID NO:2
Vehicle
SEQ ID NO:2
M31
32
36
37
33
34
38
39
40



% SurvivinmRNA levels in Tumour
140
120
100
80
60
40
20
Vehicle
SEQ ID NO:2

Fig. 10A




Fig. 10B

